1. an oral drug (trade name Lipitor) that is effective in lowering triglycerides; potent in reducing LDL cholesterol because higher doses can be given (同)Lipitor

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/09/02 19:49:37」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression.
  • Tabuchi T, Satoh M, Itoh T, Nakamura M.SourceDivision of Cardiology, Department of Internal Medicine and Memorial Heart Center, Iwate Medical University School of Medicine, Iwate, Japan.
  • Clinical science (London, England : 1979).Clin Sci (Lond).2012 Aug 1;123(3):161-71.
  • Endothelial senescence is thought to play a role in CAD (coronary artery disease). miR-34a (microRNA-34a) and other SIRT1 (silent information regulator 1)-related miRs have recently been found to target SIRT1 leading to endothelial senescence. In the present study, we investigated whether SIRT1-rela
  • PMID 22364258
  • Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome: A Post Hoc ATTEMPT Analysis.
  • Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP; for the Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group.Source1Department of Internal Medicine, Second Propedeutic Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Angiology.Angiology.2012 Jul;63(5):358-366. Epub 2011 Oct 17.
  • This post hoc analysis of the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) study assesses the 3½ year incidence of new-onset diabetes (NOD) and related cardiovascular disease (CVD) events in patients with metabolic syndrome (MetS), after mult
  • PMID 22007026

Japanese Journal

  • Selected Papers : Kovarnik T, Mintz GS, Skalicka H, et al : Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration : HEAVEN study : Circ J 76 : 176-183, 2011 : HEAVEN試験について
  • 室原 豊明
  • Cardio-lipidology : 脂質代謝から考える心血管系 6(3), 122-124, 2012-12
  • NAID 40019544194
  • アトルバスタチンはロスバスタチンよりも急性冠症候群患者の腎機能低下を抑制する
  • 桑原 昌則,近藤 史明,濱田 知幸 [他]
  • 日本心臓病学会誌 : Journal of cardiology. Japanese edition 7(3), 194-198, 2012-10
  • NAID 40019462657
  • Combination Therapy of Atorvastatin and Amlodipine Inhibits Sympathetic Nervous System Activation and Improves Cognitive Function in Hypertensive Rats
  • KISHI Takuya,SUNAGAWA Kenji
  • Circulation journal : official journal of the Japanese Circulation Society 76(8), 1934-1941, 2012-07-25
  • … biBackground:/i/b A previous study has demonstrated that orally administered atorvastatin reduces sympathetic nervous system (SNS) activation via an anti-oxidant in the rostral ventrolateral medulla (RVLM) of hypertensive rats, whereas amlodipine did not. … Furthermore, several previous reports have suggested that atorvastatin or amlodipine improves cognitive dysfunction during hypertension. …
  • NAID 10030504660

Related Links

Atorvastatin (INN) (pron.: /əˌtɔrvəˈstætən/), marketed by Pfizer as a calcium salt under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes ...
2009年2月7日 ... リピトール(Lipitor)は、米ファイザー社が製造・販売する高脂血症治療薬...




cytochrome C450 3A4
  • 多くの薬物を代謝するので薬物相互作用を起こしやすい。





アトルバスタチンカルシウム水和物 atorvastatin calcium hydrate
リピトール Lipitorカデュエット


  • [display]